All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
During the 8th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub was pleased to speak to María-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES. We asked, What are the current and future strategies for maintenance therapy after autologous transplant?
What are the current and future strategies for maintenance therapy after autologous transplant?
Mateos begins by discussing the aims of maintenance therapy and outlines the current standard of care (lenalidomide), in addition to newer therapies such as proteasome inhibitors and monoclonal antibodies. Finally, Mateos discusses the importance of determining the optimal duration of therapy.
In which scenarios a PI added to Rd maintenance could benefit patients with MM after auto-HSCT?
During the 63rd ASH Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to María-Victoria Mateos, University Hospital of...
Monthly theme | An introduction to patient reported outcomes (PROs) and quality of life (QoL) assessments in multiple myeloma
This article will introduce PROs and QoL assessments in MM, as well as set the scene for the content that will be following...
Subscribe to get the best content related to multiple myeloma delivered to your inbox